Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBD-anti-CTLA4
- Development stage
- Preclinical
- Lead developer
- Imperial College London
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CBD-anti-CTLA4 is an engineered recombinant fusion protein designed to improve the therapeutic index of CTLA-4 checkpoint inhibition. It consists of an anti-CTLA4 monoclonal antibody fused to a collagen-binding domain (CBD) derived from the von Willebrand Factor (vWF) A3 domain. This construct is designed to target the tumor microenvironment by binding to exposed collagen in the tumor stroma after intravenous administration. By localizing the antibody specifically within tumor tissues, the drug achieves deep tissue infiltration and efficient depletion of intratumoral regulatory T cells (Tregs) while significantly reducing systemic exposure and associated toxicities, such as hepatotoxicity. Developed by researchers at Imperial College London, CBD-anti-CTLA4 has demonstrated superior anti-tumor efficacy and complete tumor regression in preclinical models of glioblastoma, melanoma, and breast cancer.
- Other names
- collagen-binding anti-CTLA4CBD-anti-CTLA4 antibodyCBD-anti-CTLA-4 antibodyCBD-anti-CTLA 4 antibodyCBD + anti-CTLA4
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on CBD-anti-CTLA4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBD-anti-CTLA4.